EP2307016A4 - Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate - Google Patents

Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Info

Publication number
EP2307016A4
EP2307016A4 EP09803180A EP09803180A EP2307016A4 EP 2307016 A4 EP2307016 A4 EP 2307016A4 EP 09803180 A EP09803180 A EP 09803180A EP 09803180 A EP09803180 A EP 09803180A EP 2307016 A4 EP2307016 A4 EP 2307016A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonate
salt
preventing
pharmaceutical composition
treating osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09803180A
Other languages
German (de)
English (en)
Other versions
EP2307016A2 (fr
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Young Goo Jin
Ki Yoon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong Wha Pharm Co Ltd
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of EP2307016A2 publication Critical patent/EP2307016A2/fr
Publication of EP2307016A4 publication Critical patent/EP2307016A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP09803180A 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate Withdrawn EP2307016A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20080075791 2008-08-01
KR1020090007774A KR20100014090A (ko) 2008-08-01 2009-01-31 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
PCT/KR2009/004295 WO2010013975A2 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Publications (2)

Publication Number Publication Date
EP2307016A2 EP2307016A2 (fr) 2011-04-13
EP2307016A4 true EP2307016A4 (fr) 2011-12-28

Family

ID=42087985

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09803180A Withdrawn EP2307016A4 (fr) 2008-08-01 2009-07-31 Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate

Country Status (6)

Country Link
EP (1) EP2307016A4 (fr)
JP (1) JP2011529876A (fr)
KR (2) KR20100014090A (fr)
CN (1) CN102149381A (fr)
CA (1) CA2732864A1 (fr)
WO (1) WO2010013975A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
WO2010013969A2 (fr) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
JP2016534124A (ja) * 2013-08-29 2016-11-04 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 代謝並びに体重関連疾患の処置のための組成物および方法
WO2016054105A1 (fr) 2014-09-29 2016-04-07 A123 Systems, LLC Anodes de silicium pré-lithiées avec liant pvdf

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001991A1 (fr) * 1999-07-01 2001-01-11 Merck & Co., Inc. Comprimes pharmaceutiques
WO2004056373A1 (fr) * 2002-12-20 2004-07-08 F. Hoffmann-La Roche Ag Formulation d'ibandronate a forte dose
WO2007089101A1 (fr) * 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind.Co., Ltd. Nouveaux dérivés de benzamidine, procédé de fabrication et composition pharmaceutique les renfermant
WO2009017222A1 (fr) * 2007-08-02 2009-02-05 Teijin Pharma Limited Agent préventif ou agent thérapeutique pour une maladie provoquée par un métabolisme osseux anormal

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
CA2278190A1 (fr) * 1997-02-04 1998-08-06 Hong-Suk Suh Derive 3-amino-1,2-benzoisoxazole, procede de preparation et utilisation
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
JP2003292453A (ja) * 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JPWO2005002590A1 (ja) * 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
CA2528805A1 (fr) * 2003-08-13 2005-05-06 Chiron Corporation Inhibiteurs de gsk-3 et utilisations
CN1950086A (zh) * 2004-04-28 2007-04-18 默克公司 作为雄激素受体调节剂的氟化的4－氮杂甾族化合物
JP4657296B2 (ja) * 2004-07-05 2011-03-23 ドン ファ ファーマシューティカル カンパニー リミテッド 骨折治療用薬学的組成物
JP2009017222A (ja) * 2007-07-04 2009-01-22 Panasonic Corp 色調整装置、色調整方法および色調整装置の集積回路
WO2010013969A2 (fr) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001991A1 (fr) * 1999-07-01 2001-01-11 Merck & Co., Inc. Comprimes pharmaceutiques
WO2004056373A1 (fr) * 2002-12-20 2004-07-08 F. Hoffmann-La Roche Ag Formulation d'ibandronate a forte dose
WO2007089101A1 (fr) * 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind.Co., Ltd. Nouveaux dérivés de benzamidine, procédé de fabrication et composition pharmaceutique les renfermant
WO2009017222A1 (fr) * 2007-08-02 2009-02-05 Teijin Pharma Limited Agent préventif ou agent thérapeutique pour une maladie provoquée par un métabolisme osseux anormal

Also Published As

Publication number Publication date
WO2010013975A3 (fr) 2010-06-03
CN102149381A (zh) 2011-08-10
CA2732864A1 (fr) 2010-02-04
KR20100014090A (ko) 2010-02-10
EP2307016A2 (fr) 2011-04-13
WO2010013975A2 (fr) 2010-02-04
KR20100014174A (ko) 2010-02-10
JP2011529876A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
HK1206651A1 (en) Implant for tissue engineering
PT2345410T (pt) Composição farmacêutica para libertação modificada
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
HK1144375A1 (en) Transdermal delivery system
IL200077A0 (en) Transdermal delivery systems
FI2068839T4 (fi) Nilotinibia tai sen suolaa käsittäviä farmaseuttisia koostumuksia
HK1170490A1 (zh) 用於青光眼的治療或預防的醫藥組合物
EP2251024A4 (fr) Médicament d'origine végétale destiné à prévenir ou améliorer l'hyperuricémie
IL198284A0 (en) Processes for preparing palonosetron salts
EP2193795A4 (fr) Composition pharmaceutique aqueuse contenant du latanoprost
EP2368559A4 (fr) Composition pour empêcher ou traiter l'athérosclérose
EP2327402A4 (fr) Composition contenant 4-o-méthylhonokiol pour traiter ou prévenir des maladies liées aux amyloïdes
EP2301543A4 (fr) Composition pharmaceutique pour traiter le diabète
EP2307016A4 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose comprenant un dérivé de benzamidine ou un sel de celui-ci, et du bisphosphonate
HK1145446A1 (en) Pharmaceutical composition for losing weight or treating hyperlipidemia
EP2151451A4 (fr) Composition pour empêcher ou traiter une maladie pulmonaire
HK1139052A1 (en) Composition for transdermal administration
HK1145399A1 (en) Pharmaceutical composition for treating hemorrhoids
EP2170878A4 (fr) Nouveaux dérivés de benzamidine, procédé de préparation correspondant et composition pharmaceutique les contenant qui permet de prévenir ou de traiter l'ostéoporose
IL201912A0 (en) Aqueous pharmaceutical composition
EP2307015A4 (fr) Composition pharmaceutique pour prévenir ou traiter l'ostéoporose à base de dérivés de benzamidine ou de sels de ceux-ci, et d'acide alendronique ou de sels de celui-ci
EP2417972A4 (fr) Composition pharmaceutique destinée au traitement ou à la prévention des brûlures
HK1120034A1 (en) Pharmaceuticals for treating or preventing oral diseases
EP2266578A4 (fr) Composition pharmaceutique destinée à traiter la résorption osseuse d étiologies différentes
EP2077114A4 (fr) Préparation pharmaceutique pour le traitement de la fibromyalgie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20111118BHEP

Ipc: A61K 31/663 20060101ALI20111118BHEP

Ipc: A61P 19/10 20060101ALI20111118BHEP

Ipc: A61K 31/426 20060101AFI20111118BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130802